Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of adding gemtuzumab ozogamicin to conventional chemotherapy for adult acute myeloid leukemia: a systematic review and meta-analysis

Published:2021-12-27 Issue:1 Volume:27 Page:53-64
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Guo Yuancheng¹^ORCID,Deng Lijuan²,Qiao Yanhong³,Liu Bei¹⁴^ORCID

Affiliation:

1. The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of China

2. Shaanxi Provincial People's Hospital, Shaanxi, People’s Republic of China

3. Xi’an Central Hospital, Xi’an, People’s Republic of China

4. Department of Hematology, The First Affiliated Hospital, Lanzhou University, Lanzhou, People’s Republic of China

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2013410

Reference22 articles.

1. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges

3. Acute myeloid leukaemia

4. Gemtuzumab ozogamicin for acute myeloid leukemia

5. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience;Frontiers in Immunology;2023-12-22

2. Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023;Cancers;2023-05-31